It will measure progression-free survival (PFS) as its primary endpoint ... with zilovertamab vedotin in patients with diffuse large B-cell lymphoma, compared to the current standard treatment.” ...

One published study showed median PFS of 3.6 months and median OS of 12.9 months. Epcoritamab-bysp has been approved for adults with relapsed or refractory DLBCL or follicular lymphoma who have ...

Matthew Matasar, MD, discussed what the findings from the ELM-1 trial of odronextamab in diffuse large B-cell lymphoma mean ...

and previous studies of the combination in relapsed or refractory DLBCL have demonstrated poor outcomes. Thus, the median PFS of placebo plus lenalidomide plus rituximab of only 2.6 months is not ...

Durations of response ranged from 63 to 644 days for patients with FL and from 34 to 685 days for patients with DLBCL. Patients with FL had a median PFS of 317 days (95% CI: 112–575) and ...

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid neoplasm. Three subtypes have been identified by gene-expression studies; germinal center (GC) DLBCL, non-GC DLBCL, and ...

Progression-free survival (PFS): the amount of time a patient lives with a disease ... efficacy and manageable safety in heavily pretreated patients with R/R DLBCL and other B-cell malignancies. At ...

These investigators used SEER data to compare the outcomes of transformed indolent non-Hodgkin lymphomas with de novo DLBCL at a population level, a situation for which little data exist.

MSD has started a phase 3 trial of ROR1-directed zilovertamab vedotin (zilo-V) as a treatment for previously untreated diffuse large B-cell lymphoma ... free survival (PFS), with overall survival ...

The primary endpoint is progression-free survival (PFS), and secondary endpoints include ... for the treatment of relapsed or refractory DLBCL and in the Phase 2 waveLINE-007 trial (NCT05406401 ...

Diffuse large B-cell lymphoma (DLBCL) is the most common type ... 80% (relapsed); 20% (refractory) PFS: 15.1 months (relapsed); 2.0 months (refractory) 12-months PFS: 35% Treatment-emergent ...